Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms
The open IND gives Cerecin clearance to proceed with the next phase of the planned development for CER-0001 in IS.
- The open IND gives Cerecin clearance to proceed with the next phase of the planned development for CER-0001 in IS.
- IS usually affects children under the age of 36 months and can lead to cognitive, neurologic and sensory problems.
- The disorder is commonly treated with hormonal medications (such as adrenocorticotropic hormone and prednisolone) and vigabatrin, an anticonvulsant.
- Cerecin’s pilot study of CER-0001 is ongoing and will have recruited the 10th and final patient by 1H 2023.